Discover Great Companies Discover Great Clients
Popularity  7.6万   |   Followers  71   |   Likes  34   |   Feedback  62 Claim this company

Extraction, purification, and production of heparin

No.86 Nanjing City Popularity Ranking No.13 Pukou District No.381 Jiangsu Pr No.1 Clinical Biotechnology Chemistry No.1 Biotechnology Chemistry No.1 Biotechnology Chemical No.2 Zhu She Liquids No.2 Nutrition Food No.2 Generic Drugs No.3 Kang Zhong Liu Yao No.3 Yi Yao Ji Group No.3 Chemistry Pharmaceuticals No.4 Pharmaceutical APIs No.4 Peptides No.5 APIs 省级高新技术企业 高新技术企业 企业技术中心 理事长单位 国家高新技术企业 市级创新型中小企业 EDQM认证 PMDA认证 MHRA认证
More

Company Overview

  • Nature: Listed Company Size: 1000-4999 employees Founded: 26年
  • Industry: Pharmaceutical/Bioengineering
  • Full name: Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.。

Development Stage

  • Stage: IPO, 。
  • Ranking: Ranked #86 in Nanjing City by popularity Ranked #1 in Nanjing Clinical Biotechnology Chemistry Company by popularity Ranked #1 in Nanjing Biotechnology Chemistry Company by popularity Ranked #1 in Nanjing Biotechnology Chemical Company by popularity Ranked #2 in Nanjing Zhu She Liquids Company by popularity
  • Honors: 2025中国新经济500强 2025中国医药工业100强 省级高新技术企业 高新技术企业 According to algorithm
  • News: 2026-07-27:健友股份:门冬胰岛素注射液获美国FDA批准。
  • Salary: 52.2% of positions earn 8-15K, In 2026 vs last yeargrew by 24%.。Master's salary: ¥24.7K, Doctorate salary: ¥45.0K.
  • R&D: "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 25.5%, "Other (R&D and Technical)": 15.7%, "Mechanical/Instrumentation": 8.2%。
  • Recruiting: In 2026 vs 2025decreased by 4%. Demand for highly educated talent: Master's: 22, Doctorate: 1.
  • Requirement: Education: 本科 leads with 52.9%. Experience: 不限 leads with 28.8%.
  • Region: Distributed across 1 regions, 南京: 92%, 哈尔滨: 0.9%, 合肥: 0.7%, 南昌: 0.7%.

About the Company

[Summary] Extraction, purification, and production of heparin

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a pharmaceutical group company integrating production, research, and sales. The company entered the heparin sodium industry in 1987 and was listed on the A-share market of the Shanghai Stock Exchange on July 19, 2017, with a market value exceeding 40 billion yuan.

The company has a diversified industrial layout, currently involving APIs, preparations, internet platforms, CDMO, and hotels. It owns several subsidiaries, including Chengdu Jianjin, Hong Kong King-friend, US MH, and operations in Israel.

The company is a major global producer of heparin sodium, with over 30 years of experience in heparin production. Heparin sodium is an anticoagulant and antithrombotic drug for cardiovascular and cerebrovascular diseases. It is a mandatory medication in European and American markets and a basic drug in China's medical insurance, mainly sold to Europe, the United States, Germany, Brazil, Japan, and other regions.

The company's products are primarily filed in both China and the US. Currently, its marketed products cover areas such as anticoagulation and antithrombosis, cardiovascular and cerebrovascular diseases, anti-tumor drugs, anesthetics, and surgical adjuncts. It is one of the few domestic companies that have passed quality certifications from the US FDA, EU EDQM, Japan PMDA, Brazil ANVISA, and the UK MHRA. The company holds honors such as High-tech Enterprise of Jiangsu Province and Postdoctoral Innovation Practice Base of Jiangsu Province.

In terms of preparation marketing, the company deeply strengthens interaction with the internet wave. As a pioneer in the internetization of the pharmaceutical field, it has formed a marketing and support team of over 100 people, including pharmaceutical marketing, academic promotion, and internet software support, with domestic preparation sales growing at a multiple rate each year.

Through thirty years of hard work, the company upholds the pure piety of pharmaceutical professionals, always practicing the mission and responsibility of "driving domestic drug development with international standards, entering the international drug market with international capabilities, and striving for the health and well-being of society and humanity." It remains true to its original aspiration, shoulders responsibility, and continuously works to promote Chinese injectable products to go global and expand in the international market.



【Talent Development Policy】

1. The company will adopt a three-level training approach at the "company level, department level, and position level." New employees are assigned mentors and receive "one-on-one" work guidance, using the "JI decomposition" training method to ensure they quickly integrate into the company.

2. The company has a complete dual-channel career development system: the management channel and the technical channel. The company organizes promotion applications quarterly, evaluating personnel through both management and technical aspects.

3. The company has a comprehensive training system, organizing regular annual training at the company and department levels, conducting ad-hoc job training (including special topics, documents, management, and other categories), and also arranging external training based on different job needs.



【Welfare and Incentive Policies】

1. Regular welfare: five social insurances and one housing fund, supplementary medical insurance for children, annual physical examination, holiday benefits, paid leave, shuttle bus, working meals, and accommodation for non-local staff.

2. Incentive benefits: performance-based salary, year-end bonus, equity incentives, and two salary adjustments per year.

Working hours:

Non-production positions: five days on and two days off, 8:15-17:00.

Production positions: four days on and two days off (specific working hours are based on production plans).

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

King-friend Shares Products & Services (1 in total)

0 reviews
公司的肝素是从猪小肠粘膜提取的多糖生化物,由于通常以其钠盐形式存在故称“肝素钠”。肝素具有很强的抗凝血、抗血栓功能,在临床上主要用于抗凝血、抗血栓的治疗;同时也是生产低分子肝...
Manage

King-friend Shares Financing History (2 rounds)

Manage
IPO
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal:

King-friend Shares How Fast Is Hiring Growing? (123 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 84%
  • 2024: Down 26%
  • 2023: Up 175%
  • 2022: Down 46%
King-friend Shares Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
King-friend Shares Campus Recruitment & Advanced Degree Talent Demand
Graduates 2 Part-time 1 Master's 22 Doctorate 1
Note: How fast is hiring at Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. growing? King-friend Shares2026: 318 openings (down 4%), 2025: 332 openings (up 84%), 2024: 180 openings (down 26%), 2023: 242 openings (up 175%), 2022: 88 openings (down 46%), 2021: 162 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

King-friend Shares Master's Degree Job Demand Analysis

(More)
How fast is master's hiring at Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. growing? . King-friend Shares master talent ranking in Nanjing: #45, King-friend Shares master salary mostly around 20-50K.

King-friend Shares Doctoral Degree Job Demand Analysis

(More)
N/A
Growth Rate
King-friend Shares Doctoral Hiring by Year: 2026
* Hiring was generally low during 2020-2022 due to the pandemic
No.99
Doctoral Demand Ranking in Nanjing City 򀀩
¥30-50K and above
Doctoral Salary 򀀩
How fast is doctoral hiring at Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. growing? King-friend SharesDoctorate recruitment over the years: 2026: 6 openings (down 4%), 2022: 1 openings (down 46%). King-friend Shares doctorate talent ranking in Nanjing: #99, King-friend Shares doctorate salary mostly around 30-50K and above.

King-friend Shares R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.? Based on an analysis of King-friend Shares's job postings over the past year, "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 25.5%, "Other (R&D and Technical)": 15.7%, "Mechanical/Instrumentation": 8.2%, "Medical & Health/Beauty & Healthcare": 6.8%, "Scientific Research": 4.9%, "Electrical/Energy/Power": 3.5%. For reference only.

King-friend Shares — What Are the Salaries Like? (427 records)

Manage
salary range: 3K - 50K, 52.2% of roles pay ¥8-15K
Note: salary statistics are based on 427 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.?King-friend Shares52.2% of positions earn 8-15K, Fresh graduate salary: ¥14.9K。Nanjing salary ranking top 20,工厂生产类 average salary ¥13.3K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of King-friend Shares

(More)
Are salaries high at Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.? We provide: Quality, Technical Expert, Finance Specialist, Leasing Manager, Analyst, Researcher, Business Development, QA, 事务主管, Workshop, HR, 临床, 合规, Information, Production Supervisor, Provincial Manager, Sales, 税务, Planning Specialist, Securities Specialist. Click to view detailed salary analysis by job.

King-friend Shares — Fortune 500? (More)

Yes, ranked in 中国新经济500强:

  • NO.475 2025中国新经济500强 >
  • NO.482 2024中国新经济500强 >
  • NO.354 2023中国新经济500强 >

Yes, ranked in 中国医药工业100强:

  • NO.76 2025中国医药工业100强 >
  • NO.82 2024中国医药工业100强 >
  • NO.90 2023中国医药工业100强 >

King-friend Shares honors, qualifications & industry associations

Job Category

  • 工厂生产类
    29.3% of total 29.3%
  • 生物/制药/化工/环保类
    25.5% of total 25.5%
  • 经营管理类
    23% of total 23%
  • 质量管理类
    18% of total 18%

Education

  • 本科
    52.9% of total 52.9%
  • 大专
    32.3% of total 32.3%
  • 硕士
    10.8% of total 10.8%
  • 博士
    1.4% of total 1.4%

Experience

  • 不限
    28.8% of total 28.8%
  • 3-5年
    28.1% of total 28.1%
  • 5-10年
    21.5% of total 21.5%
  • 1-3年
    20.6% of total 20.6%
View Detailed Analysis

What does Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. require? Who is King-friend Shares hiring? King-friend Shares recruitment: 工厂生产类占比最多占29.3%,其次是生物/制药/化工/环保类占25.5%. What education can get in at King-friend Shares? 本科占比最多占52.9%,其次是大专占32.3%. High education required at King-friend Shares? 硕士占10.8%,博士占1.4%. Work experience required at King-friend Shares? 不限占比最多占28.8%,其次是3-5年占28.1%. Where are the job locations at King-friend Shares? 南京占比最多占92%,其次是哈尔滨占0.9%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 161,563.4969万(元)
Legal Representative: 唐咏群
Date Established:
Credit Code: 91320100726054999R
Registered Address: 南京高新开发区MA010-1号地

Partners & Suppliers

向健友股份供应肝素钠原料药 Source
供应商 肝素钠原料药采购客户
为公司提供年度财务报表审计服务 Source
供应商 审计服务
公司制剂产品的区域分销合作 Source
合作客户 制剂分销
公司制剂产品的国内分销商 Source
合作客户 制剂分销
公司制剂产品的国内配送及分销 Source
合作客户 制剂分销

People who follow King-friend Shares also follow

King-friend Shares Competitors (Similar Companies)

生物科技/生物工程 医药 基因合成 生物医药
“Health for Humanity, Creating a Better Future Together”
“Innovative chemical products and services provider in the drug researc”
软膏剂 医药工业 原料药 制药/药业
“Manufacturing "biochips" to provide source power for the development o”
“Seek and strive, protect and heal all beings”
“A renowned enterprise in China's liver disease and anti-tumor fields”
制药/药业 中成药 医药 药物研发
医药 抗肿瘤药 化学合成药 肿瘤药物
“A Top 500 Chinese enterprise integrating seven major industries includ”
“主营医药中间体、原料药和成品药的研发、生产与销售”
“It is a high-tech pharmaceutical R&D and production enterprise integra”
“To develop high-quality biologics that are accessible and affordable f”
余热回收 加热炉 工程总承包/EPC 研发
“To become an internationally competitive biotechnology enterprise”

Discover Great Companies, Discover Great Clients

南京公司名录 南京“Pukou District”公司名录 南京“制药/药业”公司名录 南京“医药”公司名录 南京“生物化学”公司名录 南京“化学制药”公司名录 南京“药物研发”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates